Point Therapeutics News
Most Popular Point Therapeutics Story
Talabostat trials put on hold on discouraging data
Regulators have dealt another blow to Point Therapeutics, putting their late-stage trials of the lung cancer therapy talabostat on clinical hold based on interim results. The company announced that Read more...
Latest Headlines
- July 27, 2007
- July 12, 2007
- May 30, 2007
- January 11, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
